Press

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with FDA

Dec 7 • 3 min read

PsyBio Therapeutics Corp. (TSXV: PSYB), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the successful completion of its initial pre-Investigational New Drug application meeting with the United States Food and Drug Administration as part of the regulatory submission process. “PsyBio was created…

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Dec 6 • 4 min read

Mydecine Innovations Group (NEO: MYCO), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s…

Awakn Life Sciences Strengthens Executive Leadership Team

Dec 3 • 2 min read

Awakn Life Sciences Corp. (NEO: AWKN), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the execution of an agreement to appoint Kate Butler as new Chief Financial Officer, and Jonathan Held, current Chief Financial Officer, to transition to Awakn’s Chief Business Officer. Under the terms of the…

Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia

Dec 2 • 2 min read

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received confirmation from the U.S. Food and Drug Administration that its review of Tryp’s Investigational New Drug application is complete and that the Company may proceed with its clinical study in fibromyalgia. The…

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

Dec 2 • 5 min read

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note and shares of Seelos common stock to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435